Starting hormone replacement therapy after 60 is not the same evidence conversation as starting near menopause.
The 2022 North American Menopause Society position statement says the benefit-risk ratio is favorable for women younger than 60 or within 10 years of menopause onset who have no contraindications and need treatment for bothersome vasomotor symptoms or bone-loss prevention. For women who start hormone therapy after age 60 or more than 10 years from menopause onset, the ratio appears less favorable because absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia are higher. [1]
That does not mean every woman over 60 is banned from systemic hormone replacement therapy. It means the decision needs a clearer indication, a narrower dose and route discussion, and a better baseline-risk review than a vague "try hormones for wellness" plan.
Bottom line
After age 60, systemic hormone replacement therapy should be symptom-led and risk-sorted. Severe hot flashes that continue after other options fail are a different indication from fatigue, weight change, skin aging, "hormone optimization," or disease-prevention hopes.
The first decision is whether the symptom actually requires systemic therapy. Genitourinary syndrome of menopause may be treated with local vaginal options rather than whole-body estrogen. Hot flashes may be treated with nonhormonal prescriptions when systemic hormones are a poor fit. Bone protection may require a bone-specific plan rather than late systemic hormone initiation. [1]
An eligibility-aware assessment is useful because age is only one variable. The late-start decision also depends on years since menopause, blood pressure, low-density lipoprotein, diabetes, smoking, migraine with aura, prior clot or stroke, coronary disease, breast cancer history, liver disease, unexplained bleeding, uterus status, progestogen need, route, dose, and medication interactions.
The evidence is limited in a practical way: population trial data can identify timing-related risk patterns, but they cannot decide that a specific 62-year-old with severe night sweats, low cardiovascular risk, and no contraindications has the same tradeoff as a 72-year-old with coronary disease, unexplained bleeding, and a vague wellness goal.
Starting after 60 is different from continuing after 60
One common confusion is mixing two separate questions:
| Question | What it means | Why it matters |
|---|---|---|
| Starting systemic hormone replacement therapy for the first time after 60 | A new exposure begins when age and baseline vascular risk are higher. | Menopause Society describes a less favorable benefit-risk ratio for initiation after 60 or more than 10 years from menopause. [1] |
| Continuing hormone replacement therapy after 60 or 65 | A person who started earlier is reassessing whether benefits still outweigh risks. | The decision still needs periodic review, but it is not the same evidence question as first starting late. [1] |
| Restarting after years off therapy | A new initiation decision after a gap. | Treat this closer to late initiation than simple continuation. |
| Switching route or dose after 60 | Exposure continues, but risk may change by route, dose, and progestogen. | Route and dose may matter, but they do not erase baseline contraindications. [4] |
That distinction prevents two mistakes: scaring every long-term user into abrupt stopping, and treating a brand-new late start as if it has the same evidence profile as early symptom treatment.
What Women's Health Initiative timing analyses actually found
A Women's Health Initiative secondary analysis evaluated age and years since menopause across randomized hormone-therapy trials. For women less than 10 years from menopause onset, the hazard ratio for coronary heart disease was 0.76, with a 95% confidence interval from 0.50 to 1.16. For women 20 or more years from menopause, the hazard ratio was 1.28, with a 95% confidence interval from 1.03 to 1.58. [2]
The absolute coronary heart disease estimate also changed with timing: -6 events per 10,000 person-years within 10 years of menopause versus 17 excess events per 10,000 person-years at 20 or more years from menopause. [2]
| Timing group in Women's Health Initiative analysis | Coronary heart disease hazard ratio | Absolute-risk direction |
|---|---|---|
| Less than 10 years from menopause | 0.76, 95% confidence interval 0.50 to 1.16. [2] | Estimated 6 fewer CHD events per 10,000 person-years. [2] |
| 10 to 19 years from menopause | Intermediate pattern in the analysis. [2] | Not a clean permission zone. |
| 20 or more years from menopause | 1.28, 95% confidence interval 1.03 to 1.58. [2] | Estimated 17 excess CHD events per 10,000 person-years. [2] |
This is why the timing hypothesis is cautious, not permissive. It supports the idea that timing matters. It does not establish that hormone replacement therapy should be prescribed to prevent coronary disease in early menopause.
Stroke, clot, and dementia risk are separate from the coronary timing story
The same Women's Health Initiative timing analysis found hormone therapy increased stroke risk overall, with a hazard ratio of 1.32 and 95% confidence interval from 1.12 to 1.56. Stroke risk did not clearly vary by age or years since menopause in that analysis. [2]
Venous thromboembolism risk also matters more as baseline risk rises with age, obesity, thrombophilia, prior clot, smoking, immobility, and some medical conditions. The American College of Obstetricians and Gynecologists route-of-administration opinion notes that orally administered estrogen may exert a prothrombotic effect, while transdermal estrogen may have little or no effect on prothrombotic substances, though the individual risk profile still matters. [4]
Menopause Society also includes dementia among the absolute risks that become more relevant when therapy starts after age 60 or more than 10 years from menopause onset. [1] The practical point is not that every late-start prescription causes dementia. It is that late initiation should not be presented as a brain-health shortcut.
HRT is not a heart or chronic-disease prevention plan
American College of Obstetricians and Gynecologists states that menopausal hormone therapy should not be used for primary or secondary prevention of coronary heart disease. It also notes that healthy women in early menopause with vasomotor symptoms may be candidates for symptom relief. [3]
U.S. Preventive Services Task Force makes the prevention boundary even broader. Its 2022 recommendation advises against combined estrogen-progestin therapy for primary prevention of chronic conditions in postmenopausal persons with a uterus and against estrogen alone for that purpose in postmenopausal persons who have had hysterectomy. [5]
That distinction is central after 60. A symptom-led decision may still exist. A prevention-led decision should be treated skeptically.
| Goal | Better frame after 60 |
|---|---|
| Severe hot flashes or night sweats | Compare systemic hormone replacement therapy against nonhormonal options, route, dose, and personal risk. [1] |
| Vaginal dryness, painful sex, recurrent urinary symptoms from genitourinary syndrome of menopause | Consider local vaginal estrogen, vaginal dehydroepiandrosterone, ospemifene, moisturizers, or other genitourinary syndrome of menopause-specific options before systemic hormone replacement therapy. [1] |
| Heart disease prevention | Do not use systemic hormone replacement therapy for this goal. [3] [5] |
| Dementia prevention or brain optimization | Do not use late systemic hormone replacement therapy as a cognitive-protection shortcut. [1] |
| Bone protection | Compare fracture risk and bone-specific therapies rather than treating late systemic hormone replacement therapy as the default. [1] |
| General anti-aging, weight loss, skin, or energy | Weak indication; investigate other causes and avoid broad hormone promises. |
The late-start screening matrix
The safest after-60 decision is explicit about what would make systemic therapy reasonable and what would make it a poor fit.
| Review item | Why it matters after 60 |
|---|---|
| Specific symptom target | Systemic hormone replacement therapy is easier to justify for severe vasomotor symptoms than vague wellness goals. |
| Years since menopause | Menopause Society describes a less favorable ratio after age 60 or more than 10 years from menopause. [1] |
| Blood pressure, low-density lipoprotein, diabetes, smoking, family history | Baseline cardiovascular risk changes absolute risk. |
| Stroke, TIA, migraine with aura, clot, thrombophilia, coronary disease | These may make systemic therapy inappropriate or specialist-led. |
| Breast cancer history or high breast-risk context | Requires individualized oncology or menopause-specialist review. |
| Uterus status | Systemic estrogen usually needs endometrial protection if the uterus is present. [1] |
| Unexplained vaginal bleeding | Bleeding needs evaluation before hormone decisions. |
| Route and dose | Transdermal and lower-dose strategies may change some risk discussions, but they do not erase contraindications. [4] |
| Current medicines | Anticoagulants, blood-pressure drugs, migraine therapies, seizure medicines, and CYP interactions can matter. |
| Local or nonhormonal alternatives | If the symptom can be treated without systemic hormone replacement therapy, the risk-benefit balance may change. |
Who may still have a reasonable discussion
Starting systemic hormone replacement therapy after 60 may be reasonable to discuss when symptoms are severe, clearly menopause-related, persistent, and not controlled with lower-risk options, and when the person has no major contraindications after individualized cardiovascular, clot, breast, liver, bleeding, and uterus-status review.
It may also be discussed when the route, dose, progestogen plan, and follow-up are intentionally conservative rather than borrowed from a younger-person template. "Lowest effective dose" and periodic reassessment matter more when baseline risks are higher.
Who should usually avoid shortcutting
Late initiation is a poor fit when the goal is heart prevention, dementia prevention, longevity, weight loss, skin aging, fatigue without workup, or vague hormone optimization. [3] [5]
It also deserves a hard pause when there is unexplained postmenopausal bleeding, prior breast cancer or estrogen-sensitive cancer complexity, prior stroke or TIA, active or prior venous thromboembolism, known high-risk thrombophilia, coronary heart disease, uncontrolled hypertension, active liver disease, high baseline cardiovascular risk, or severe migraine/stroke-risk history.
These are not minor side notes. They are the difference between a symptom-treatment decision and an unsafe hormone shortcut.
What to ask a clinician
- Are we starting systemic hormone replacement therapy for the first time after 60, continuing earlier therapy, or restarting after years off?
- What exact symptom are we treating, and how will we measure success?
- How many years has it been since my final menstrual period, and how does that change benefit-risk?
- Would nonhormonal hot-flash medicine, local vaginal estrogen, vaginal dehydroepiandrosterone, ospemifene, moisturizers, pelvic care, or bone-specific treatment fit the symptom better?
- What are my blood pressure, low-density lipoprotein, diabetes status, smoking status, ASCVD risk, clot history, stroke history, migraine history, liver history, and breast-risk context?
- If systemic therapy is still on the table, should route, dose, and progestogen plan be changed because I am starting after 60?
- What bleeding, chest, neurologic, clot, breast, liver, or severe headache symptoms mean I should stop and seek urgent evaluation?
Women's Health Initiative follow-up reporting is one reason the page separates symptom treatment from chronic-disease prevention: the randomized hormone-therapy trials tracked benefits and harms across intervention and post-stopping phases rather than giving a simple age-agnostic endorsement. [6]
Related reading:
- Hormone therapy after menopause: benefits, risks, and timing.
- hormone replacement therapy contraindications after menopause.
- Transdermal vs oral estrogen.
- hormone replacement therapy after 65: how long can you take hormone therapy?.
- Vaginal estrogen after menopause.
References
[1] “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/gme.0000000000002028 https://pubmed.ncbi.nlm.nih.gov/35797481/
[2] Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-77. doi:10.1001/jama.297.13.1465 https://pubmed.ncbi.nlm.nih.gov/17405972/
[3] ACOG Committee Opinion No. 565: Hormone therapy and heart disease. Obstet Gynecol. 2013;121(6):1407-1410. doi:10.1097/01.aog.0000431053.33593.2d https://pubmed.ncbi.nlm.nih.gov/23812486/
[4] ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol. 2013;121(4):887-890. doi:10.1097/01.aog.0000428645.90795.d9 https://pubmed.ncbi.nlm.nih.gov/23635705/
[5] US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(17):1740-1746. doi:10.1001/jama.2022.18625 https://pubmed.ncbi.nlm.nih.gov/36318127/
[6] Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353-68. doi:10.1001/jama.2013.278040 https://pubmed.ncbi.nlm.nih.gov/24084921/